9:55 AM · 10 October 2024

GlaxoSmithKline surges 5% on Zantac settlement deal in the US

Shares of British pharmaceutical giant, GlaxoSmithKline (GSK.US) more than 5% today amid $2.2 billion settlement deal in US Zantac lawsuits, caused by 'cancer-casuing' concerns. The deal will resolve 93% (almost 80,000) of US lawsuits. The company will recognize this loss in Q3 results, this year. All the settlements are expected to be implemented by the end of the first half of 2025. GSK confirmed also another $70 million paid to resolve the Zantac so-called qui tam complaint previously filed by Valisure. This agreement is pending final approval from the Department of Justice. Investors positively react to this news, improving 'uncertainty' about Zantac case.

 

Source: xStation5

 
 

 

8 September 2026, 2:44 PM

US Open: NFP Has Shifted Fed Expectations, and Wall Street Now Awaits Inflation

8 September 2026, 12:58 PM

ASML is picking up pace again.

8 September 2026, 11:37 AM

Novartis shares fall the most since 2020 📉 What is behind the 10% decline?

7 September 2026, 1:58 PM

Market Wrap: Far-right AfD wins in Germany, oil continues to rise (07.09.2026)

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits